Abstract:Alessandra Bartoli, 1, 2 Carmela Cursaro, 1 Hajrie Seferi, 1 Pietro Andreone 3, 4 1 Division of Internal Medicine and Metabolism, Department of Internal Medicine, Ospedale Civile di Baggiovara, University of Modena and Reggio Emilia, Modena, Italy; 2 Post Graduate School of Allergy and Clinical Immunology, Department of Internal Medicine, University of Modena and Reggio Emilia, Modena, Italy; 3 Chief of Division of Internal Medicine and metabolism, Department of Internal Medicine, University Hospital of Modena, Modena, Italy; 4 Chief of Post Graduate School of Allergy and Clinical Immunology, Department of Internal Medicine, University of Modena and Reggio Emilia, Modena, Italy Correspondence: Alessandra Bartoli, University of Modena and Reggio Emilia, Ospedale Civile di Baggiovara, Via Pietro Giardini 1355, Baggiovara, MO, 41126, Italy, Email Purpose: From the beginning of the Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS-CoV2) pandemic, different cases of a cholangiopathy with features of secondary sclerosing cholangitis in critically ill patients (SSC-CIP) have been reported. Patients developing it are generally recovering from severe Coronavirus disease 19 (COVID-19) and required intensive care unit (ICU) admission and mechanical ventilation. Many of them have been administered with ketamine during their ICU stay. The pathogenesis of this novel disease is still debated, and, since prognosis is poor, efforts are needed in order to better understand it. Patients and Methods: In this review, we focused our attention on COVID-19 SSC clinical, imaging, and histology findings in order to clarify the different pathogenetic options, particularly in regard of the ischemic-direct viral damage and ketamine-related theories, beginning with a recapitulation of SSC-CIP and ketamine-induced cholangiopathy in abusers. The research has been conducted using PubMed and Google Scholar databases. Key-words were "Secondary Sclerosing Cholangiopathy", "SSC-CIP", "Secondary Sclerosing Cholangiopathy in critically ill patients", "Ketamine and cholangiopathy", "Ketamine abusers and liver disease", "Ketamine-related cholangiopathy", "SARS-CoV2 infection and liver disease", "post Covid-19 secondary sclerosing cholangitis", "Covid-19 cholangiopathy". Results: Many authors, based on the clinical, histological, imaging, and prognostic features of the disease, have pointed out the similarities between post COVID-19 SSC and SSC-CIP; however, peculiar features in the former were not previously observed. Therefore, a direct viral cytopathic action and SARS-CoV2-related coagulopathy are considered the most likely causes. On the other hand, ketamine, with the available data, cannot be surely linked as the main determinant cause of cholangiopathy. Moreover, ketamine-induced cholangitis (KIC) presentation is different from post COVID-19 SSC. Its role as a cofactor precipitating the disease cannot be ruled out. Conclusion: Post COVID-19 SSC is a rare clinical entity following severe COVID-19 disease. The most accepted theory is that a sum of different insults determines the disease: biliary ischemia, direct viral damage, toxic bile, possibly worsened by ketamine and hyperinflammation due to the cytokine storm. Given the severe prognosis of the disease, with persistent cholangiopathy, organ failure, and orthotopic liver transplantation (OLT), further study on this novel clinical entity is needed. Keywords: SARS-CoV2, cholangiopathy, secondary sclerosing cholangiopathy, ICU, SSC-CIP, ketamine, COVID-19 coagulopathy, direct viral damage From December 2019 a new pandemic spreading all around the world is responsible for millions of deaths and morbidity. Coronavirus disease 19 (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV2), a β-coronavirus isolated for the first time in Wuhan, China. COVID-19 is typically characterized by respiratory symptoms, culminating in bilateral interstitial pneumonia followed, in the most severe cases, by an abnormal activation of the immune system. This cytokine storm, if not controlled, can determine tremendous consequences such as ARDS, heart failure, acute renal insufficiency, liver failure, and death. 1 In hospitalized COVID-19 patients, a mild-moderate elevation of liver enzyme is frequent (14–58% of cases), with aspartate aminotransferase (AST) reaching higher values than alanine aminotransferase (ALT). 2 Transaminase elevation is generally observed at the beginning of hospital stay, with an improvement during hospitalization. 3–5 The increase of transaminases and total bilirubin is known to be a risk factor for poor outcome in severe COVID-19. 6 Tw -Abstract Truncated-

COVID-19-associated secondary sclerosing cholangitis - A case series of 4 patients

Post-COVID-19 Secondary Sclerosing Cholangitis: A Rare but Severe Condition with no Treatment Besides Liver Transplantation

Secondary Sclerosing Cholangitis due to Severe COVID-19: An Emerging Disease Entity?

Endoscopic Characterization and Outcome of COVID-19 Patients with Secondary Sclerosing Cholangitis: A Case Series of a Tertiary Center

COVID-19-Related Cholangiopathy: Histological Findings

Incidence of Secondary Sclerosing Cholangitis in Hospitalized Long COVID-19 Patients: A Retrospective Single Center Study

Secondary sclerosing cholangitis in a young COVID-19 patient resulting in death: A case report

Secondary sclerosing cholangitis in critically ill patients: a rare disease precipitated by severe SARS-CoV-2 infection

COVID-19-associated secondary sclerosing cholangitis with liver transplantation

Secondary Sclerosing Cholangitis Following Coronavirus Disease 2019 (COVID-19): A Multicenter Retrospective Study

Post-COVID-19 cholangiopathy: Systematic review

Secondary Sclerosing Cholangitis in a Critically Ill Patient with Severe SARS-CoV-2 Infection: A Possibly Emergent Entity during the Current Global Pandemic

Hepatobiliary long-term consequences of COVID-19: dramatically increased rate of secondary sclerosing cholangitis in critically ill COVID-19 patients

Endosonographic and ERCP findings in COVID-19 critical illness cholangiopathy

Secondary sclerosing cholangitis induced by systemic chemotherapy

Biliary Cast Syndrome and Secondary Sclerosing Cholangitis in Critically Ill Patient after Long-Term Treatment in the Intensive Care Unit

Secondary sclerosing cholangitis after intensive care unit treatment: clues to the histopathological differential diagnosis

COVID-19 related biliary injury: A review of recent literature

Secondary Sclerosing Cholangitis After SARS-CoV2: ICU Ketamine Use or Virus-Specific Biliary Tropism and Injury in the Context of Biliary Ischemia in Critically Ill Patients?

S2421 Duct and Cover: A Case of Post-COVID-19 Cholangiopathy Requiring Biliary Cast Removal

S4526 Post COVID-19 Cholangiopathy With Portopulmonary Hypertension: A Case Report